For instance, several studies have documented a beneficial effect of ceftriaxone on the misfolding of glial fibrillary acidic protein (GFAP) in in vitro and in vivo models of Alexander’s disease (AxD), a genetic astrogliopathy [105,106], and on the misfolding of α-syn in dopaminergic neurons in experimental models of PD and in dementia with Lewy bodies [7,107,108]. The gene discussed is GFAP; the disease is Parkinson disease.